Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers

Gao, Rebecca W.; Teraphongphom, Nutte; Boer, Esther de; Berg, Nynke S. van den; Divi, Vasu; Kaplan, Michael; Oberhelman, Nicholas J.; Hong, Steven; Capes, Elissa; Colevas, A. Dimitrios; Warram, Jason M.

doi:10.7150/thno.24487

Cited by 134 publications

(132 citation statements)

References 25 publications

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…A frequently used dye for fluorescence guiding purposes is IRDye800CW, which has been conjugated to multiple targeting moieties and is increasingly used for clinical FGS in various solid tumor types. [67][68][69] We have developed a clinical grade exendin-4-IRDye800CW conjugate and shown feasibility of insulinoma targeting and imaging in mice with subcutaneous GLP-1R overexpressing Chinese hamster lung cell tumors. 70 We intent to start clinical trials in which this tracer is employed for FGS of insulinoma.…”

Section: Fluorescence Imaging For Intraoperative Detection Of Insulmentioning

confidence: 99%

Exendin‐4 analogs in insulinoma theranostics

Jansen

Lith

Boss

et al. 2019

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

Insulinomas are neuroendocrine tumors arising from the pancreatic beta cells. Currently, surgical resection is the therapy of choice, and therefore, preoperative localization of insulinomas is essential. Nearly all insulinomas show overexpression of the glucagon‐like peptide‐1 receptor (GLP‐1R), and therefore, radiolabeled GLP‐1 peptide analog exendin‐4 can be used for diagnosis and preoperative localization with nuclear imaging. Here, we present an overview of the development and clinical implementation of exendin‐4–based tracers for single‐photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging of insulinomas, and we address the potential use of this molecule for optical imaging. At last, we discuss the possibilities and pitfalls of the use of exendin‐4–based tracers for therapeutic applications such as peptide receptor radionuclide therapy (PRRT) or targeted photodynamic therapy (tPDT), giving a future outlook on the use of exendin‐4 in insulinoma theranostics.

show abstract

Section: Fluorescence Imaging For Intraoperative Detection Of Insulmentioning

confidence: 99%

Exendin‐4 analogs in insulinoma theranostics

Jansen

Lith

Boss

et al. 2019

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

show abstract

“…[ 16 ] However, long‐term toxicity and immunogenicity, non‐biodegradability, as well as photo‐instability of these non‐life‐like materials have restricted their translation into clinical applications. [ 17–22 ] Thus, the development of new fluorophores with increased biocompatibility and biosafety as imaging diagnostic tools is essential for biomedical application.…”

Section: Figurementioning

confidence: 99%

Engineered Near‐Infrared Fluorescent Protein Assemblies for Robust Bioimaging and Therapeutic Applications

Sun

et al. 2020

Advanced Materials

View full text Add to dashboard Cite

Near-infrared (NIR) fluorescence imaging is an evolving field enabling high-resolution imaging and diagnosis in biomedicine. Due to the reduced photon scattering and minimal tissue absorption, fluorescence imaging in the NIR window Fluorescent proteins are investigated extensively as markers for the imaging of cells and tissues that are treated by gene transfection. However, limited transfection efficiency and lack of targeting restrict the clinical application of this method rooted in the challenging development of robust fluorescent proteins for in vivo bioimaging. To address this, a new type of near-infrared (NIR) fluorescent protein assemblies manufactured by genetic engineering is presented. Due to the formation of well-defined nanoparticles and spectral operation within the phototherapeutic window, the NIR protein aggregates allow stable and specific tumor imaging via simple exogenous injection. Importantly, in vivo tumor metastases are tracked and this overcomes the limitations of in vivo imaging that can only be implemented relying on the gene transfection of fluorescent proteins. Concomitantly, the efficient loading of hydrophobic drugs into the protein nanoparticles is demonstrated facilitating the therapy of tumors in a mouse model. It is believed that these theranostic NIR fluorescent protein assemblies, hence, show great potential for the in vivo detection and therapy of cancer.(700-1700 nm) offers increased tissue penetration depths and a better signal-to-noise ratio rendering it ideal for biomedical applications. [1][2][3][4][5][6][7] Currently, NIR fluorescent materials mainly comprise quantum dots, [8][9][10] lanthanide-doped upconverting nanoparticles, [11][12][13] organic small molecules, [14,15] and polymer-based systems. [16] However, long-term toxicity and immunogenicity, non-biodegradability, as well as photo-instability of these non-life-like materials have restricted their translation into clinical applications. [17][18][19][20][21][22] Thus, the development of new fluorophores with increased biocompatibility and biosafety as imaging diagnostic tools is essential for biomedical application.Fluorescent proteins (FPs), such as redshifted fluorescent protein and engineered monomeric near-infrared fluorescent proteins (mIFPs), were proven to be excellent candidates for noninvasive labeling and whole-body imaging in living organisms due to the low light scattering/background noise, reduced autofluorescence, and relatively easy construction procedure. [23][24][25][26][27][28][29][30] Typically, those fluorophores are genetically encoded and must be produced by gene transfection into living cells and animals for bioimaging. However, the transfection efficiency is limited and the FPs expressed by this procedure are unable to target tumors effectively owing to the lack of specific binding sites. [31,32] Moreover, FPs that are expressed by hosts such as Escherichia coli and yeast are rarely reported for direct in vivo bioimaging. This most likely stems from the fast photobleaching in blood protease...

show abstract

“…[115][116][117][118][119][120] Moreover, OTL38, an NIRF agent binding with folate receptor-α has entered Phase III clinical trial stage for patients with ovarian cancer [121] and Phase II clinical trial stage for patients with pulmonary adenocarcinomas. Rosenthal and co-workers devoted a considerable amount of efforts in researching tumor-specific fluorescent probes by conjugating antibodies (e.g., panitumumab, cetuximab, etc.)…”

Section: Fluorescence Imagingmentioning

confidence: 99%

Advanced Nanotechnology Leading the Way to Multimodal Imaging‐Guided Precision Surgical Therapy

et al. 2019

View full text Add to dashboard Cite

Surgical resection is the primary and most effective treatment for most patients with solid tumors. However, patients suffer from postoperative recurrence and metastasis. In the past years, emerging nanotechnology has led the way to minimally invasive, precision and intelligent oncological surgery after the rapid development of minimally invasive surgical technology. Advanced nanotechnology in the construction of nanomaterials (NMs) for precision imaging-guided surgery (IGS) as well as surgery-assisted synergistic therapy is summarized, thereby unlocking the advantages of nanotechnology in multimodal IGS-assisted precision synergistic cancer therapy. First, mechanisms and principles of NMs to surgical targets are briefly introduced. Multimodal imaging based on molecular imaging technologies provides a practical method to achieve intraoperative visualization with high resolution and deep tissue penetration. Moreover, multifunctional NMs synergize surgery with adjuvant therapy (e.g., chemotherapy, immunotherapy, phototherapy) to eliminate residual lesions. Finally, key issues in the development of ideal theranostic NMs associated with surgical applications and challenges of clinical transformation are discussed to push forward further development of NMs for multimodal IGS-assisted precision synergistic cancer therapy.

show abstract

Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers

Cited by 134 publications

References 25 publications

Exendin‐4 analogs in insulinoma theranostics

Exendin‐4 analogs in insulinoma theranostics

Engineered Near‐Infrared Fluorescent Protein Assemblies for Robust Bioimaging and Therapeutic Applications

Advanced Nanotechnology Leading the Way to Multimodal Imaging‐Guided Precision Surgical Therapy

Contact Info

Product

Resources

About